Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

Saved in:
Bibliographic Details
Published inJournal of pharmacokinetics and pharmacodynamics Vol. 47; no. 3; pp. 187 - 188
Main Authors Okour, Malek, Al-Kofahi, Mahmoud, Austin, Daren
Format Journal Article
LanguageEnglish
Published New York Springer US 01.06.2020
Springer Nature B.V
Subjects
Antibiotics
Azithromycin
Azithromycin - therapeutic use
Betacoronavirus - drug effects
Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Clinical Trials as Topic
Commentary
Coronavirus Infections - diagnosis
Coronavirus Infections - drug therapy
Coronavirus Infections - physiopathology
Coronavirus Infections - virology
COVID-19
Drug Therapy, Combination
Humans
Hydroxychloroquine
Hydroxychloroquine - blood
Hydroxychloroquine - pharmacokinetics
Hydroxychloroquine - therapeutic use
Immunomodulators
Models, Biological
Pandemics
Pharmacology/Toxicology
Pharmacy
Pneumonia, Viral - diagnosis
Pneumonia, Viral - drug therapy
Pneumonia, Viral - physiopathology
Pneumonia, Viral - virology
SARS-CoV-2
Treatment Outcome
Veterinary Medicine/Veterinary Science
Viral Load - drug effects
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1567-567X
1573-8744
1573-8744
DOI:10.1007/s10928-020-09689-x